What is the recommended diagnostic workup and initial management for a euvolemic patient with hypotonic hyponatremia suggestive of Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)?

SIADH: Diagnostic Workup and Initial Management

For a euvolemic patient with hypotonic hyponatremia suggestive of SIADH, confirm the diagnosis with serum and urine osmolality plus urine sodium, then initiate fluid restriction to 1 L/day as first-line therapy for mild-to-moderate cases, reserving hypertonic saline only for severe symptomatic presentations. 1, 2, 3

---

Diagnostic Confirmation

Essential Laboratory Criteria (Five Cardinal Features)

SIADH requires all five of the following to be present 2, 4:

• Hypotonic hyponatremia: serum sodium <135 mmol/L (typically <134 mEq/L) with serum osmolality <275 mOsm/kg 2, 3, 4
• Inappropriately concentrated urine: urine osmolality >100 mOsm/kg (typically >300–500 mOsm/kg) despite low serum osmolality 2, 3, 4
• Elevated urine sodium: typically >20–40 mEq/L, reflecting continued sodium excretion despite hyponatremia 2, 3, 4
• Clinical euvolemia: absence of edema, orthostatic hypotension, dry mucous membranes, or other signs of volume depletion or overload 1, 2, 4
• Normal renal, thyroid, and adrenal function: must exclude hypothyroidism (check TSH), adrenal insufficiency (check morning cortisol), and renal failure (check creatinine) 1, 2, 4

Supportive Diagnostic Tests

• Serum uric acid <4 mg/dL has a 73–100% positive predictive value for SIADH, though this can also occur in cerebral salt wasting 1, 2
• Plasma ADH levels are NOT recommended—they do not alter management and delay diagnosis 1

Critical Differential: SIADH vs. Cerebral Salt Wasting (CSW)

In neurosurgical patients or those with CNS pathology, distinguishing SIADH from CSW is essential because they require opposite treatments 1, 2:

• SIADH: euvolemic, CVP 6–10 cm H₂O, urine Na >20–40 mEq/L, treat with fluid restriction 1, 2
• CSW: hypovolemic with orthostatic changes, CVP <6 cm H₂O, urine Na >20 mEq/L despite volume depletion, treat with volume and sodium replacement 1, 2

---

Initial Management Algorithm

Step 1: Assess Symptom Severity

Severe symptomatic hyponatremia (seizures, coma, altered mental status):

• Immediate ICU transfer for close monitoring 2, 3
• Administer 3% hypertonic saline with goal to correct 6 mmol/L over 6 hours or until severe symptoms resolve 2, 3
• Monitor serum sodium every 2 hours during initial correction 2, 3
• Total correction must NOT exceed 8 mmol/L in 24 hours to prevent osmotic demyelination syndrome 1, 2, 3

Mild symptomatic or asymptomatic hyponatremia (sodium <120 mEq/L without severe symptoms):

• Fluid restriction to 1 L/day is first-line therapy 2, 3
• Monitor sodium every 4 hours initially, then daily 2, 3
• Expected correction rate: approximately 1.0 mEq/L/day with fluid restriction alone 3, 5

Step 2: Identify and Treat Underlying Cause

Common causes of SIADH 2, 4, 6:

• Malignancy: especially small cell lung cancer (SCLC), which produces vasopressin 2, 4
• CNS disorders: meningitis, encephalitis, head trauma, subarachnoid hemorrhage 2, 4
• Pulmonary diseases: pneumonia, tuberculosis, positive-pressure ventilation 2, 4
• Medications: SSRIs, carbamazepine, oxcarbazepine, NSAIDs, opioids, chemotherapy (cisplatin, vincristine, cyclophosphamide) 2, 7
• Post-operative state: iatrogenic from hypotonic IV fluids 2, 4

Discontinue offending medications immediately if symptomatic hyponatremia is present 2, 7

Step 3: Second-Line Pharmacological Options (If Fluid Restriction Fails)

• Demeclocycline: induces nephrogenic diabetes insipidus, reducing kidney response to ADH; considered second-line when fluid restriction is ineffective 2, 3
• Urea (0.25–0.50 g/kg/day): highly effective for chronic SIADH, induces osmotic water drive, well-tolerated long-term (though 54% report distaste) 3
• Tolvaptan (vasopressin receptor antagonist): FDA-approved for clinically significant euvolemic hyponatremia; starting dose 15 mg once daily, titrate to 30–60 mg as needed 1, 5

---

Critical Safety Considerations

Correction Rate Limits to Prevent Osmotic Demyelination Syndrome

• Standard-risk patients: maximum 8 mmol/L in 24 hours 1, 2, 3
• High-risk patients (advanced liver disease, chronic alcoholism, malnutrition, prior encephalopathy): maximum 4–6 mmol/L per day 1, 2, 3
• Chronic hyponatremia (>48 hours duration): slower correction is safer to prevent late-onset neurological complications 2, 6

Special Populations Requiring Modified Approach

• Subarachnoid hemorrhage patients at risk for vasospasm: NEVER use fluid restriction—this worsens outcomes and increases cerebral ischemia risk; consider fludrocortisone or hydrocortisone instead 1, 2, 3
• Older adults: age is an independent risk factor for SIADH development, particularly with psychotropic drugs (SSRIs, carbamazepine) 2, 7
• Post-operative patients: hospitalization often worsens hyponatremia due to iatrogenic excess of hypotonic IV fluids combined with reduced salt intake 8

---

Common Pitfalls to Avoid

• Failing to obtain appropriate laboratory tests: serum/urine osmolality and urine sodium were obtained in <50% of patients in the Hyponatremia Registry, yet success rates in correcting hyponatremia were significantly higher when these tests were performed 5
• Using fluid restriction in cerebral salt wasting: this is a critical error that worsens hypovolemia and can be fatal 1, 2
• Overly rapid correction: occurred in 10.2% of patients in the Registry, risking osmotic demyelination syndrome 5
• Inadequate monitoring during active correction: check sodium every 2 hours for severe symptoms, every 4 hours for mild symptoms 1, 2
• Discharging patients still hyponatremic: 75% of patients in the Registry were discharged with sodium <135 mEq/L, and 43% with sodium ≤130 mEq/L, indicating suboptimal management 5
• Ignoring the underlying cause: failing to identify and treat the precipitating factor (malignancy, medication, CNS disorder) leads to recurrence 1, 2